Experience

• • Clayton, Dubilier & Rice in the financing aspects of its bid for a controlling stake in Opella, the French-headquartered consumer healthcare company, valuing the company at c.€16 billion.
  • LGT Capital Partners in the formation of Crown Global Secondaries VI, a $7 billion+ private equity secondaries fund.
  • ICG in the formation of ICG LP Secondaries I, a $1 billion fund specializing in acquiring buyout fund interests from limited partners.
  • Ara Partners in the closing of over $3 billion in new commitments to Ara Fund III, an industrial decarbonization fund, and dedicated limited partner co-investment vehicles.
  • Clayton, Dubilier & Rice in the formation of Clayton, Dubilier & Rice Fund XII, an approximately $26 billion fund, its largest fund to date.
  • Tikehau Capital in its $300 million inaugural collateralized fund obligation.
  • Tristan Capital, the pan-European real estate investment manager, in its sale of a 31% interest in Tristan to Candriam, a New York Life affiliate, taking Candriam’s total stake in Tristan to 80%.
  • Clayton, Dubilier & Rice in the financing aspects of its acquisitions of Atalian and OCS to create a global facilities management platform.
  • Ara Partners, a private equity firm specializing in industrial decarbonization investments with an ESG focus, in the formation of Ara Fund II, a $1.1 billion industrial decarbonization fund.
  • Clayton, Dubilier & Rice in its sale of a minority stake in Belron to Hellman & Friedman, BlackRock and GIC, which valued the company at €21 billion.
  • CANDRIAM and its affiliate New York Life Investments Alternatives in their strategic partnership with Kartesia Management, a private credit manager, and the related acquisition of a minority stake in the firm.
  • TPG in the sale of Adare Pharmaceuticals, a leading specialty contract development and manufacturing organization, to Thomas H. Lee Partners and Frazier Healthcare Partners and the related separation of Adare’s Eosinophilic Esophagitis product into a TPG-backed entity.